MICHELLE FISH: Open Payments
NPI 1104341684 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$597 in 13 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $634 · 2025 $597
Food & beverage: $597
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $137 |
| Regeneron Pharmaceuticals, Inc. | 1 | $124 |
| Boston Scientific Corporation | 1 | $117 |
| Janssen Biotech, Inc. | 4 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| GENZYME CORPORATION | 1 | $42 |
| Ferring Pharmaceuticals Inc. | 1 | $27 |
Products named: DUPIXENT, WallFlex Duodenal, TREMFYA, ENTYVIO, REBYOTA, LINZESS.
Industry payments across IN — which companies pay providers there.
